Skip to main content
. 2024 Jan 24;13(2):116. doi: 10.3390/antibiotics13020116

Table 1.

Demographics and characteristics of the kidney transplant recipients with urinary tract infection by Escherichia coli and Klebsiella pneumoniae.

Variables E. coli
115 Episodes
N (%)		 K. pneumoniae
69 Episodes
N (%)
Age (years; median [IQR]) 58 (50–67) 61 (50–69)
Female patients 71 (61.7) 42 (60.9)
Charlson Comorbidity Index (median [IQR]) 3 (3–5) 5 (3–5)
Months from transplantation (median [IQR]) 14 (4–77) 6 (1–77)
<2 months from transplantation 21 (18.3) 41 (59.4)
Previous kidney transplantation 10 (8.7) 8 (11.6)
Living donor 11 (9.5) 6 (8.7)
Induction therapy within 3 previous months:
  •       -

    Thymoglobulin

  •       -

    Basiliximab

  •       -

    Daclizumab

 73 (63.5)
26 (22.6)
41 (35.7)
6 (5.2)		 28 (40.6)
12 (17.4)
14 (20.3)
2 (2.9)
Current immunosuppression:
  •       -

    Corticosteroids

  •       -

    Tacrolimus

  •       -

    MMF

  •       -

    mTOR inhibitors

  •       -

    Cyclosporine
107 (93.0)
107 (93.0)
90 (78.3)
8 (6.9)
4 (3.4)
58 (84.1)
64 (92.8)
54 (78.3)
4 (5.8)
3 (4.3)
Acute rejection within the previous 6 months 11 (9.6) 0 (0.0)
Rejection treatment in the previous 6 months:
  •       -

    Corticosteroid’s bolus

  •       -

    Plasmapheresis

  •       -

    Thymoglobulin
9 (7.9)
1 (0.9)
1 (0.9)
-
-
-
Creatinine (mg/dL; median [IQR]) 1.57 (1.21–1.95) 1.56 (1.25–1.99)
Bacteriuria within the previous 6 months 57 (49.6) 49 (71.0)
Antibiotic use within the previous 3 months
  •       -

    Quinolones *

  •       -

    Amoxicillin-clavulanate

  •       -

    Fosfomycin

  •       -

    Cephalosporins **

  •       -

    Others ***

 48 (41.7)
11 (9.6)
6 (5.2)
14 (12.2)
15 (13.0)
2 (1.7)		 30 (43.5)
3 (4.3)
8 (11.6)
10 (14.5)
7 (10.1)
2 (2.9)
Cystitis 19 (16.5) 33 (47.8)
Asymptomatic bacteriuria 96 (83.5) 36 (52.2)
Urinary pH (median [IQR]) 6 (6–6.5) 6.5 (6–6.5)
Baseline antibiotic resistance:
  •       -

    Cotrimoxazole

  •       -

    Ciprofloxacin

  •       -

    Amoxicillin-clavulanate

  •       -

    Fosfomycin

  •       -

    Cephalosporins ****

  •       -

    ESBL-production
66 (57.4)
30 (26.1)
24 (20.9)
10 (8.7)
2 (1.7)
2 (1.7)
42 (60.9)
20 (29.0)
15 (21.7)
8 (11.6)
21 (30.4)
20 (29.0)
Antibiotic therapy of the UTI episodes
  •       -

    Fosfomycin

  •       -

    Ciprofloxacin
88 (76.5)
27 (23.5)
46 (66.7)
23 (33.3)

IQR: Interquartile range; MMF: Mycophenolate mofetil; mTOR inhibitors: Sirolimus, everolimus; ESBL: Extended spectrum beta-lactamases; * Quinolones: ciprofloxacin or levofloxacin; ** Cephalosporins: cefixime or cefuroxime; *** Others: Ertapenem, cloxacillin and rifaximine; **** Cephalosporins: cefuroxime, cefotaxime, ceftazidime, cefixime or cefepime.